Results 111 to 120 of about 58,362 (266)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

Migration of Intravitreal Silicone Oil Into the Lateral Cerebral Ventricles. [PDF]

open access: yesDtsch Arztebl Int
Yousefian Jazi E, Wegerhof A, Haddadi F.
europepmc   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi   +6 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Electro‐clinical features of Mowat–Wilson syndrome: A retrospective study of 31 children in mainland China

open access: yesEpileptic Disorders, EarlyView.
Abstract Objective To summarize the electro‐clinical and genetic characteristics of children with Mowat–Wilson syndrome (MWS). Methods This study is a hospital‐based case series analyzing clinical data from 31 pediatric patients with MWS and epilepsy treated at Peking University First Hospital between June 2020 and December 2024.
Yi Ju, Tao‐yun Ji
wiley   +1 more source

Mesial temporal lobe epilepsy with hippocampal sclerosis: Seizure, neuropsychological, and quality of life outcomes of 100 patients treated with trans‐anterior T1 selective amygdalohippocampectomy

open access: yesEpileptic Disorders, EarlyView.
Abstract Objective For mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS), laser interstitial thermal therapy has recently been increasingly used. At our institute, however, selective amygdalohippocampectomy by a trans‐anterior T1 subpial approach (trans‐anterior T1 SAH) has been used for MTLE with HS. Here, we examined the seizure,
Naotaka Usui   +11 more
wiley   +1 more source

Cognition in adults with bottom‐of‐sulcus dysplasia and the consequences of focal resection

open access: yesEpilepsia, EarlyView.
Abstract Objective To determine whether there are cognitive consequences of bottom‐of‐sulcus dysplasia (BOSD) when assessed as adults and whether focal resection of these lesions leads to change in cognition. Methods We studied 42 adults, of whom 39 underwent focal resection targeting the lesion.
Carmen J. Zheng   +4 more
wiley   +1 more source

KCNJ4 variants disrupt inward‐rectifier potassium channel function and cause refractory epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective Epilepsy is a common neurological disorder with a strong genetic basis, most frequently arising from ion channel dysfunction. Although multiple inwardly rectifying potassium (Kir) channels have been implicated in epileptogenesis, the contribution of KCNJ4, which encodes the Kir2.3 channel, has not previously been established in human
Hu Pan   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy